Determining the optimal timing of adjuvant chemotherapy initiation after concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma

被引:0
|
作者
Cheng, H. [1 ,2 ]
Chen, J. [1 ,2 ]
Jia, G. [1 ,2 ]
Liang, Y. [1 ,2 ]
Li, Y. [1 ,2 ]
Chen, Y. [1 ,2 ]
Lin, J. [1 ,2 ]
Wang, P. [1 ,2 ]
Chen, Q. [1 ,2 ]
Tang, L. [1 ,2 ]
Mai, H. [1 ,2 ]
Liu, L. [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Key Lab Nasopharyngeal Carcinoma Diag & Therapy, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Dept Nasopharyngeal Carcinoma, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China
关键词
locoregionally advanced nasopharyngeal carcinoma; adjuvant chemotherapy initiation; optimal timing; progression-free survival; RANDOMIZED-TRIAL; STAGE-III; CANCER; SURVIVAL; RADIOTHERAPY; ASSOCIATION; MULTICENTER; TIME; DNA;
D O I
10.1016/j.esmoop.2024.103707
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Studies on several malignancies have suggested that the time to commencement of adjuvant chemotherapy (AC) is associated with survival outcomes. There have, however, been no relevant reports of nasopharyngeal carcinoma (NPC). Patients and methods: This clinical study examined newly diagnosed patients between April 2017 and December 2020. The primary endpoint was progression-free survival (PFS). Inverse probability of treatment weighting was used to control for confounding factors. Cox models with restricted cubic splines, Kaplan-Meier method and log-rank tests were used to evaluate the relationship between AC timing and survival. Results: A total of 551 patients were identified [median age, 45 years (interquartile range 36-52 years); 383 (69.5%) male]. Restricted cubic splines demonstrated that the timing of AC initiation had a U-shaped association with PFS. The risk of disease progression decreased within 37 days and subsequently increased. From 37 to 90 days, each additional 7-day delay conferred worse PFS of 1.32 months {hazard ratio (HR): 1.14 [95% confidence interval (CI) 1.01-1.28], P = 0.04}. The cut-off value of the receiver operating characteristic curve for initiation was 69.5 days. At a median follow-up of 48 months, the PFS was significantly better in patients initiated within 69.5 days [HR: 2.18 (95% CI 1.17-4.06), log-rank P = 0.009], with a higher 3-year rate [78.8% (95% CI 75.1% to 82.7%) versus 59.0% (95% CI 42.2% to 82.5%)] than beyond 69.5 days. Positive results were also observed in secondary endpoints. The initiation group was an independent prognostic factor [HR: 2.28 (95% CI 1.42-3.66), P < 0.001]. Conclusions: The optimal timing of AC initiation is similar to 37 days after concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. A delay beyond 69.5 days is associated with compromised survival. Efforts should be made to address the reasons for delays and ensure the timely initiation of AC.
引用
收藏
页数:10
相关论文
共 50 条
  • [11] Concurrent chemoradiotherapy plus adjuvant chemotherapy versus chemoradiotherapy alone or radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis
    Iocca, O.
    Ferraro, E.
    Gadaleta-Caldarola, G.
    Brandi, M.
    Filippelli, G.
    Infusino, S.
    ANNALS OF ONCOLOGY, 2015, 26 : 69 - 69
  • [12] Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma A Randomized Clinical Trial
    Miao, Jingjing
    Wang, Lin
    Tan, Sze Huey
    Li, Jin-Gao
    Yi, Junlin
    Ong, Enya H. W.
    Tan, Laura L. Y.
    Zhang, Ye
    Gong, Xiaochang
    Chen, Qiuyan
    Xiang, Yan-Qun
    Chen, Ming-Yuan
    Guo, Ying
    Lv, Xing
    Xia, Wei-Xiong
    Tang, Linquan
    Deng, Xiaowu
    Guo, Xiang
    Han, Fei
    Mai, Hai-Qiang
    Chua, Melvin L. K.
    Zhao, Chong
    JAMA ONCOLOGY, 2022, 8 (12) : 1776 - 1785
  • [13] Concurrent chemoradiation followed by adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma in Korea
    Park, Kyong Hwa
    Kim, Jeong Sun
    Park, Yong
    Seo, Hee Yeon
    Park, Young Je
    Choi, In Keun
    Oh, Sang Chul
    Seo, Jae Hong
    Kim, Chul Yong
    Jung, Kwang Yoon
    Shin, Sang Won
    Kim, Yeul Hong
    Kim, Jun Suk
    Lee, Nam Joon
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (04) : 643 - 651
  • [14] Concurrent chemoradiation followed by adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma in Korea
    Kyong Hwa Park
    Jeong Sun Kim
    Yong Park
    Hee Yeon Seo
    Young Je Park
    In Keun Choi
    Sang Chul Oh
    Jae Hong Seo
    Chul Yong Kim
    Kwang Yoon Jung
    Sang Won Shin
    Yeul Hong Kim
    Jun Suk Kim
    Nam Joon Lee
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 643 - 651
  • [15] Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma
    Setakornnukul, Jiraporn
    Thephamongkhol, Kullathorn
    BMC CANCER, 2018, 18
  • [16] Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma
    Jiraporn Setakornnukul
    Kullathorn Thephamongkhol
    BMC Cancer, 18
  • [17] neo adjuvant chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma
    Abdou, Sara
    Benzerouale, Ouail
    El Gueddari, Rania
    Taouchikht, Mouna
    Fares, Houda
    Hassnaoui, Imane
    Ngbwa, Edith Tatiana
    Nouni, Karima
    Lachgar, Amine
    Elkacemi, Hanan
    Kebdani, Tayeb
    Hassouni, Khalid
    RADIOTHERAPY AND ONCOLOGY, 2024, 192 : S249 - S250
  • [18] Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma
    Wang, Fangzheng
    Jiang, Chuner
    Ye, Zhimin
    Sun, Quanquan
    Liu, Tongxin
    Xu, Min
    Wu, Peng
    Shi, Kaiyuan
    Long, Bin
    Rihito, Aizawa
    Masoto, Sakamoto
    Fu, Zhenfu
    ONCOTARGET, 2017, 8 (43) : 75544 - 75556
  • [19] Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial
    Chen, Lei
    Hu, Chao-Su
    Chen, Xiao-Zhong
    Hu, Guo-Qing
    Cheng, Zhi-Bin
    Sun, Yan
    Li, Wei-Xiong
    Chen, Yuan-Yuan
    Xie, Fang-Yun
    Liang, Shao-Bo
    Chen, Yong
    Xu, Ting-Ting
    Li, Bin
    Long, Guo-Xian
    Wang, Si-Yang
    Zheng, Bao-Min
    Guo, Ying
    Sun, Ying
    Mao, Yan-Ping
    Tang, Ling-Long
    Chen, Yu-Ming
    Liu, Meng-Zhong
    Ma, Jun
    LANCET ONCOLOGY, 2012, 13 (02): : 163 - 171
  • [20] Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis
    Tang, Si-Qi
    Xu, Cheng
    Wang, Xiao-Shuai
    Tang, Ling-Long
    Li, Wen-Fei
    Chen, Lei
    Mao, Yan-Ping
    Guo, Rui
    Liu, Qing
    Sun, Ying
    Ma, Jun
    ORAL ONCOLOGY, 2020, 105